文献速递主动脉疾病

急性Stanford B型主动脉夹层伴逆行A型壁内血肿的胸主动脉腔内修复术安全性与有效性

Safety and efficacy of thoracic endovascular aortic repair for acute Stanford type B aortic dissection with retrograde type A intramural hematoma.
PubMed 文献 · J Vasc Surg · 2023-03-13

回顾性分析52例急性Stanford B型主动脉夹层伴逆行A型壁内血肿患者接受胸主动脉腔内修复术(TEVAR)的结果。院内及30天死亡率均为0%,30天并发症率11.5%,5年累积生存率92.6%,92.3%患者随访期间升主动脉重塑良好。对于升主动脉最大直径<50 mm且壁内血肿厚度≤10 mm的选定患者,TEVAR可能是安全、有效且持久的替代治疗。

要点

  • 52例急性TBAD伴逆行TAIMH患者接受TEVAR,院内及30天死亡率均为0%。
  • 5年累积生存率92.6%,免于胸主动脉再干预率5年为90.7%。
  • 随访期间92.3%(48/52)患者升主动脉重塑良好。

核心结论

  • 对于升主动脉最大直径<50 mm且升主动脉壁内血肿厚度≤10 mm的选定急性Stanford B型主动脉夹层伴逆行A型壁内血肿患者,腔内修复可能是安全、有效且持久的替代治疗。

研究设计与样本

  • 回顾性分析2014年1月1日至2022年3月31日期间接受TEVAR治疗的急性TBAD伴逆行TAIMH患者,共52例,平均年龄52.6岁,男性42例(80.8%)。
  • 使用3D Slicer图像计算平台测量主动脉直径和距离,分析患者特征、手术、院内及随访数据和主动脉重塑情况。

主要发现

  • 从症状发作到TEVAR的中位间隔为11天(四分位距7.0-16.8天)。
  • 院内和30天死亡率均为0%,30天并发症率为11.5%。
  • 总体累积生存率1年为100%,3年为97.1%,5年为92.6%。
  • 52例中4例(7.7%)在术后10天至4个月发生逆行A型主动脉夹层,1例(1.9%)在术后4个月发生孤立性升主动脉夹层,这5例均接受治疗并在2022年3月晚期随访时存活。
  • 累积免于胸主动脉再干预率1年为93.7%,5年为90.7%;随访期间92.3%(48/52)患者升主动脉重塑良好。

临床怎么用

  • 作者认为,对于升主动脉最大直径<50 mm且升主动脉壁内血肿厚度≤10 mm的选定急性Stanford B型主动脉夹层伴逆行A型壁内血肿患者,腔内修复可能是安全、有效且持久的替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate safety and efficacy of thoracic endovascular aortic repair (TEVAR) for acute Stanford type B aortic dissection (TBAD) with retrograde type A intramural hematoma (TAIMH). METHODS: Patients with acute TBAD with retrograde TAIMH treated with TEVAR between January 1, 2014, to March 31, 2022, were retrospectively reviewed. Aortic diameter and distance were measured using the 3D Slicer image computing platform. Patients' characteristics, procedural, in-hospital and follow-up data, and aortic remodeling were analyzed. RESULTS: Fifty-two patients (average age, 52.6 years; 42 males [80.8%]) were included. The median interval from symptom onset to TEVAR was 11 days (interquartile range, 7.0-16.8 days). The maximal diameter of the ascending aorta (AA) was <50 mm, and the hematoma thickness in the AA was ≤10 mm in all patients. Both the in-hospital and 30-day mortality rates were 0%. The 30-day complication rate was 11.5%. The overall cumulative survival rates were 100% at 1 year, 97.1% at 3 years, and 92.6% at 5 years. Four of 52 patients (7.7%) developed retrograde type A aortic dissection at 10 days to 4 months postoperatively, and one of 52 patients (1.9%) developed an isolated AA dissection 4 months postoperatively; these five patients were treated and alive at late follow-up in March 2022. The rates of cumulative freedom from thoracic aortic re-intervention were 93.7% at 1 year and 90.7% at 5 years. Positive AA remodeling was observed in 92.3% (48/52) of patients during follow-up. The maximal diameter of AA (mean ± standard error of mean) at admission was 42.7 ± 0.8 mm, which decreased to 39.5 ± 0.9 mm at last follow-up. The maximal AA hematoma thickness at admission was 7.6 ± 0.3 mm, which reduced to 2.2 ± 0.9 mm at last follow-up. CONCLUSIONS: For selected patients of acute Stanford TBAD with retrograde TAIMH, endovascular repair may be a safe, effective, and durable alternative treatment, if the maximum diameter of the AA is <50 mm and the intramural hematoma thickness in the AA is ≤10 mm.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang J, Li M, Li J, et al. Safety and efficacy of thoracic endovascular aortic repair for acute Stanford type B aortic dissection with retrograde type A intramural hematoma. J Vasc Surg. 2023. PMID: 36921645. doi:10.1016/j.jvs.2023.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。